

NEW APPROACHES RELATED TO THE USE OF POLYAMINE-FREE AND POLYAMINE-DEFICIENT DIETS IN THE LIST OF NUTRITIONAL PRODUCTS FOR COVID-19 PATIENTS

AVAGYAN S.A.¹, ZILFYAN A.V.^{2*}, MURADYAN A.A.²

¹ Scientific Research Center, Yerevan state Medical University after M. Heratsi, Yerevan, Armenia

² Department of Urology and Andrology, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia

Receive 20.01.2022; accepted for printing 30.05.2022

ABSTRACT

Researches aimed at finding effective means of pathogenetic therapy for this viral infection are extremely relevant. Researches of the last three years have established that some human pathogenic coronaviruses – MERS, SARS-CoV and SARS-CoV-2, contain aliphatic polyamines in their structure, which participate in the packaging of genetic material (DNA, RNA), as well as the nucleocapsid. Virus-host cell interactions also provide adhesion processes on the surface of the cytoplasmic membrane of target cells. In the intracellular space, aliphatic polyamines actively affect the translation and replication processes of the genetic material and necessary proteins of the virus itself, as well as the formation of daughter viruses. Long-term persistence in the SARS-CoV-2 infected organism is largely due to the absorption of polyamines by coronavirus localized in target cells of the blood and parenchymatous organs. Unfortunately, the above new facts did not serve as a prerequisite for finding effective means of pathogenetic therapy for COVID-19, based on the inhibition of polyamine-dependent processes that ensure long-term persistence of SARS-CoV-2 in the infected organism. We are talking about specific drugs such as α -difluoromethylornithine and its analogues, which are successfully used in oncology in the complex treatment of malignant neoplasms with the aim of lowering the level of aliphatic polyamines in the affected areas of malignantly transformed organs.

We recommend the use of polyamine-free and polyamine-deficient diets for COVID-19 for the first time.

In the planned study, we will present tables with food products of animal and vegetable origin, characterized by extremely low content and/or absence of aliphatic polyamines in them. At the same time, food products with a high content of aliphatic polyamines should be excluded from the general list of products recommended for COVID-19 patients.

We also recommend the use of a polyamine-deficient diet (with a preventive purpose) during the COVID-19 pandemic to a wide contingent of practically healthy individuals, convalescents, medical staff of specialized infectious disease clinics, as well as family members of SARS-CoV-2 infected patients.

KEYWORDS: COVID-19, SARS-CoV-2, polyamines, polyamine-free diet, polyamine-deficient diet.

The search for effective means of symptomatic and pathogenetic therapy for COVID-19 infection is one of the actual problems of modern medicine [Zilfyan A et al., 2020; Avagyan S et al., 2020; Chen Y et al., 1922; Rosenberg E et al., 2022; Xie Y et al., 2022].

Currently, the main scientific developments are based on creating vaccines, with the aim of preventing a wide contingent of practically healthy

individuals from SARS-CoV-2 infection, including reinfection of convalescents, as well as individuals with chronic diseases [Zilfyan A et al., 2021; Abu-Raddad L et al., 2021; Hotez P, Bottazzi M, 2022; Zheng C et al., 2022]. Besides the fact that the effectiveness of all commercial vaccines that have passed the final stage of certification is time-tested, with such an immuno-prophylactic approach, it is necessary to periodically assess the immune status, and, at least, the state of the respi-

CITE THIS ARTICLE AS:

Avagyan SA, Zilfyan AV, Muradyan AA; New approaches related to the use of polyamine-free and polyamine-deficient diets in the list of nutritional products for COVID-19 patients; NAMJ v.16 (2022) no.6, p. 4-24; DOI: <https://doi.org/10.56936/18290825-2022.16.2-14>

ADDRESS FOR CORRESPONDENCE:

Stapah A. Avagyan, PhD;

Scientific Research Center, Yerevan State Medical University after M. Heratsi 2 Koryun Street, Yerevan 0025, Armenia

E-mail: namj.ysmu@gmail.com, Tel.: (+374 93) 58-86-97

ratory, cardiovascular and digestive systems, both during coronavirus infection, and in clinical recovery period and much later [Avagyan S et al., 2021; Bajema K et al., 2021; Tenforde M et al., 2021; Cizmeci P et al., 2022; Kobayashi T, Nishiura H, 2022; Lee AR, 2022].

At present, a different scientific and methodological approach based on finding effective means of symptomatic and pathogenetic therapy for COVID-19 is much less practiced while studying the character of the infectious process caused by SARS-CoV-2 [Bitsadze B et al., 2020; Howard-Jones A et al., 2022; Kannan M et al., 2022; Rolfo A, 2022; Wang N et al., 2022].

A number of very informative studies provide data according to which, at all stages of COVID-19 infection, there are significant changes in the metabolism of polyamines localized in virus-sensitive target cells of the macroorganism [Tabor C, Tabor H, 1984; Löser C et al., 1999; Schipper R et al., 2000; Eliassen K et al., 2002; Gugliucci A, 2004; Moinard C et al., 2005; Larqué E et al., 2007; Ruíz C et al., 2012; Atiya A et al., 2013; Kalac P, 2014; Gómez G et al., 2017; Muñoz-Esparza N et al., 2019; Avagyan S et al., 2020; Zilfyan A et al., 2020; Makhoba X et al., 2022; Xu X et al., 2022].

It is established that the level of polyamines in mammals is provided by three sources:

De novo synthesis exclusively by all body cells [Lague E et al., 2007; Minois N, 2011; Ruiz C et al., 2012],

Synthesis and/or accumulation by resident microorganisms persisting in macroorganism niches [Avagyan S et al., 2019; Muñoz-Esparza N et al., 2019a, b; Romas M et al., 2019; Tofalo K et al., 2019; Zilfyan A et al., 2020],

Food intake [Gomez G et al., 2008; Atiya A et al., 2009; 2011; 2013; Ruiz C et al., 2012; Kala P, 2014; Muñoz-Esparza N et al., 2019a, b; Avagyan S et al., 2020].

Significant amounts of polyamines enter into the macroorganism with various food products that SARS-CoV-2 infected patients consume daily, without taking into account the content of polyamines in them. Thus, the situation is much more complicated, since SARS-CoV-2 is in dire need of polyamines for its activation and long-term persistence. That's why, we offer a polyamine-free and polyamine-deficient diet as auxiliary, but neces-

TABLE 1
Polyamine concentrations (nmol/g) in foods for diet groups [Soda K et al., 2009]

	Put	Spd	Spm	Total
Low polyamine diet	496	224	143	863
Normal polyamine diet	625	434	160	1219
High polyamine diet	1075	1540	374	2989

NOTES: Put - putrescine, Spd - spermidine, Spm Spermine

sary means of symptomatic and pathogenetic therapy for COVID-19, due to which it will be possible to partially stop pathological processes in target organs during this coronavirus infection.

During a paraclinical examination of a wide range of diseases of various etiologies (Parkinson's disease, Helicobacter pylori (H. pylori)-dependent gastritis, viral papilloma, breast, prostate and cervical cancer, colorectal cancer), it was found that all of them have a significantly increased level of aliphatic polyamines in plasma and erythrocytes, as well as in urine [Lewandowski N et al., 2010; Paik M et al., 2010; Chaturvedi R et al., 2012; Smythies J, 2012; Gondalia S et al., 2013].

In a number of "polyamine-dependent" diseases, where the levels of polyamines in patients were controlled by diet, the latter was divided into three groups [Shrestha R et al., 1992, Soda K et al., 2009]. The levels of polyamines in food products of each group are presented in table 1.

It should be noted that these indicators significantly differ from each other in different countries due to the lack of a single registry for assessing the intake of the optimal level of aliphatic polyamines through food products [Ralph A et al., 1999; Soda K et al., 2010; Buyukuslu N et al., 2014; Muñoz-Esparza N et al., 2019].

The average polyamine intakes by adults in countries such as the UK, Italy, Spain, Finland, Sweden and the Netherlands [Ralph A et al.,



To overcome it
is possible, due to the
uniting the knowledge and
will of all doctors in the world

1999] were 211,910 nmol/day for putrescine, 86,959 nmol/day for spermidine and nmol/day for spermine. According to the authors, in the United States, mean daily polyamine intakes were 159,133 nmol/day for putrescine, 54,697 nmol/day for spermidine and 35,698 nmol/day for spermine [Zoumas-Morse C et al., 2007]. For the population of Central Asia, the daily intake was 93057 nmol/day for putrescine, 33122 nmol/day for spermidine and 13685 nmol/day for spermine [Buyukuslu N et al., 2014].

Cipolla B. and co-authors (2003) identified three groups of products according to the content of polyamines. Products of I group (containing less than 100 nmol/g) could be taken daily, II group products (101-200 nmol/g) could be consumed three or four times a week, and III group products (>201 nmol/g) were preferable to avoid (Table 2).

By analyzing current data on the level of polyamines in food products, it is possible to make both a polyamine-free and polyamine-deficient diet specifically for patients suffering from polyamine-dependent diseases.

First of all, one can single out a polyamine-free diet, which is used in the practice of treating onco-

TABLE 2

Polyamine contents in regular food
[Cipolla B et al., 2003]

Permitted every day (<100 nmol/g)	Permitted once in a while (101-200 nmol/g)	Forbidden (>201 nmol/g)
<ul style="list-style-type: none"> • Bread • Meats, beef, veal, pork, poultry • Eggs • Fish (fresh) • Milk and white cheese • Pasta and rice • Tomatoes, onions, mushrooms, lettuce, spinach, potatoes, beetroot • Apples, pears, peaches, strawberries, grapes • Flour, margarine, butter, oil • Salt and pepper • Biscuits • Water, coffee, tea 	<ul style="list-style-type: none"> • Yoghurt • Pasteurized cheese • Jams • Wine 	<ul style="list-style-type: none"> • Carrots • Radishes • Celery • Green beans • Oranges and juice • Bananas • Prunes • Grapefruit • Melon • Liver • Fermented cheese: stilton, Roquefort, gorgonzola, camembert

TABLE 3

Polyamine-free products

Food products	Put	Spd	Spm	Cad	Total
Butter	bdl	bdl	bdl	bdl	bdl
Salt	bdl	bdl	bdl	bdl	bdl
White pepper	bdl	bdl	bdl	bdl	bdl
Black coffee	bdl	bdl	bdl	bdl	bdl
Ceylon tea	bdl	bdl	bdl	bdl	bdl
Champagne cider	bdl	bdl	bdl	bdl	bdl
Cola beverage	bdl	bdl	bdl	bdl	bdl
Curdled milk	bdl	bdl	bdl	bdl	bdl
Skimmed milk	bdl	bdl	bdl	bdl	bdl
Cream	bdl	1	bdl	bdl	1
Milk (semi-skinned, low fat)	1	bdl	bdl	bdl	1
Natural yoghurt	0.3	0.4	0.4	bdl	1.1
Egg white (freshly-laid)	1	bdl	bdl	bdl	1.0
Whisky	bdl	1	bdl	bdl	1
Cognac	bdl	1	bdl	bdl	1
Rice (white)	2.0	bdl	bdl	bdl	2.0
Soft cheese	bdl	1	1	1	3
Caster sugar	3	bdl	bdl	bdl	3.0
Very thin pancake (crepe)	bdl	5	1	1	7.0
Chocolate eclair	2	3	bdl	2	7.0
Wine vinegar	8	bdl	bdl	bdl	8.0
Mayonnaise	1	4	1	3	9.0
Honey	8	1	bdl	1	10.0
Cookie (sweet biscuit)	2	6	1	1	10.0

NOTES: Put - putrescine, Spd - spermidine, Spm - spermine, Cad - cadaverine, bdl- below detection limits

logical diseases [Moulinoux J et al., 1991; Cipolla B et al., 2003; 2007].

As can be seen from table 3, there are products in which aliphatic polyamines are not detected, and a group of products in which they are detected in extremely low quantities. We suggest products in which the total amount of polyamines is less than 10 nmol/g [Ralph A et al., 1999; Cipolla B, 2003; 2007; Buyukuslu N et al., 2014; Muñoz-Esparza N et al., 2019].

According to Cipolla B. and co-authors, the content of polyamines is very significant in some products, such as meat and meat products, culinary

products, bread products, vegetables, spices, canned foods, so they cannot be offered as polyamine-free products.

Secondly, products that can be consumed in a polyamine-deficient diet are presented in table 4 [Cipolla B et al., 2003].

Analyzing all the data presented in table 4, the levels of individual polyamines are found in the same food product, which are identical in content (Frankfurter sausage, White bread), or, conversely, significantly differ from each other. For example, Stout beer and Red table wine have much higher levels of putrescine than other polyamines. Pear and Green cabbage have much higher levels of spermidine, compared to other polyamines.

It should be especially noted that in different countries the standards for daily polyamine intake significantly differ from each other [Ralph A et al., 1999; Zoumas-Morse C et al., 2007; Muñoz-Esparza N et al., 2019; Buyukuslu N et al., 2014, Avagyan S, 2021], therefore the data of Cipolla B. and colleagues are unacceptable for other countries (USA, Japan, Turkey).

Polyamine-dependent diseases include neurological, cardiovascular and viral diseases. Their dependence on polyamine level has already been established. Taking into account the achievements of many researchers in studying the level of polyamines in products and their accessibility in the digestive tract upon their exogenous entry into the body, in some countries, it is also suggested to follow a polyamine-dependent diet for the treatment of patients with polyamine metabolism-related diseases, with the purpose of regulating the level of polyamines in the macroorganism.

Polyamine-dependent diet preparation is a very laborious process, and requires professional skills of not only nutritionists, but also general practitioners, depending on the contingent of patients who should adhere to the polyamine diet.

It has been stated that cancer patients, who have very high level of aliphatic polyamines in blood, urine and malignantly degenerated cells, are also suggested to follow a polyamine deficient diet in order to lower the level of polyamines in the macroorganism. In our opinion, decreased concentration of polyamines (spermine, spermidine and putrescine) in the body can significantly slow down

TABLE 4

Products (a partial list) that can be consumed in a polyamine-deficient diet [Cipolla B et al., 2003]

Foods	Put	Cad	Spd	Spm	Total
White wine (Burgundy)	9.0	bdl	1	bdl	10.1
Apple juice	11.1	bdl	2	bdl	13.1
Grape juice	9.0	bdl	5.1	bdl	14.1
Apricot juice	8.0	bdl	7.0	bdl	15.0
Dried milk	2.0	bdl	7.0	7.0	16.0
Prune	6.1	1	10.1	2	19.2
Pear	0.4	0.7	18.4	0.2	19.8
Freshly-laid egg	20.5	bdl	bdl	bdl	20.5
Pear	4.3	0.7	20.3	bdl	25.3
Stout beer	21.2	1	bdl	bdl	22.2
Red table wine (Bordeaux)	22.3	bdl	bdl	bdl	22.3
Peach	7.4	1	18.4	bdl	26.8
Egg yolk (freshly-laid)	43.7	bdl	bdl	bdl	43.7
Onion	5.7	3.3	35.4	bdl	44.3
Diced bacon	3	12.1	7.0	26.3	48.3
Tomato juice	35.5	1	13.2	1	50.7
Apple	30.3	0.9	22.1	bdl	53.3
Semolina	25.1	1	5.0	23.1	54.2
Red grapes	34.2	6.4	15.2	0.1	55.8
Fresh pasta	13.0	3	35.1	6.0	57.1
Green pepper	21.6	5.3	30.4	4.1	61.4
Normal ripe carrot	7.7	0.8	53.6	2.7	64.8
Toulouse sausage	3	1	16.3	46.2	66.5
Green cabbage	6.0	1	55.7	6.4	69.1
Spicy sausage (merguez)	8.1	1	12.2	48.3	69.6
Lemon	53.8	0.8	18.4	0.9	73.8
Strawberry	18.5	4.3	40.3	13.7	76.8
Chipolata	3	1	24.2	50.3	78.5
Beet, beetroot	51.7	0.2	29.1	bdl	81.0
Frankfurter sausage	11.1	14.2	27.0	31.1	83.4
Skinned potato	31.4	5.1	46.1	4.3	86.8
Pork (roast)	4	3	9.3	72.3	88.6
Turkey (wing)	14.1	2.0	10.1	68.3	94.5
White bread	13.0	15.3	54.2	13.2	95.7
String beans	65.2	bdl	27.2	6.0	98.4

NOTES: Put - putrescine, Spd - spermidine, Spm - Spermine, Cad - cadaverine, bdl- below detection limits

the course of the pathological process.

While creating a polyamine-deficient diet for patients, we analyzed the diet proposed by Ralph A. and co-authors (1999), where the daily food intake was 1500-1600 g per day, and the level of polyamines in this food was 309.54 μmol .

Considering that the average daily intake of total polyamines for healthy individuals of the European contingent is 315.1 $\mu\text{mol/day}$ (putrescine – 160.3 $\mu\text{mol/day}$, spermidine – 96.7 $\mu\text{mol/day}$ and spermine – 58.1 $\mu\text{mol/day}$) [Ralph A et al., 1999], and according to Cipolla B. and colleagues (2003), we offer 120-130 $\mu\text{mol/day}$ maximum level of polyamines in this volume of food for the polyamine-deficient diet. Under these conditions, in our opinion, it is necessary to exclude some products with a large amount of polyamines (marked with one asterisk in table 5) from the diet proposed by Ralph A. and co-authors (1999) specifically for residents of the United Kingdom, and, at the same time, adding some food products to this list that do not contain (or contain negligible amounts) polyamines (marked with two asterisks), and suggest a polyamine-deficient diet as an example (Table 5).

In this aspect, polyamine levels as diagnostic markers have not been the subject of a special study despite the fact that both coronaviruses (SARS-CoV and SARS-CoV2) need polyamines in the persistence process in an infected organism. It is for neurological, oncological and viral diseases, we propose to include a polyamine-deficient diet in the list of nutritional products, in order to reduce the level of aliphatic polyamines in the macroorganism.

Apparently, the inclusion of a polyamine diet for COVID-19 patients, in general terms, was proposed by us earlier [Avagyan S et al., 2021].

It should be especially noted that the third source of polyamine intake, with their subsequent absorption by macroorganism cells, resident microorganisms and, especially, viruses, in an infected organism was not the subject of a special study.

In this aspect, some human pathogenic coronaviruses – MERS, SARS-CoV and SARS-CoV-2, need polyamines localized in target cells and resident microorganisms in the process of long-term persistence in the macroorganism, in order to maintain their functional activity-adhesion on the

TABLE 5

Daily dietary polyamine intake in the UK in 1995 (including eating out) [Ralph A et al., 1999] #

Food	Intake (g/d)	Total ($\mu\text{mol/d}$)	
		For Normal polyamine Diet	For polyamine-deficient diet
Other cereal	69	9.371	9.371
Biscuits, cake	42	0.964	0.964
Milk, cream, yogurt	100	0.81	0.81
Eggs	14	0.079	0.079
Vegetables	166	45.207	45.207
Chocolate, sweets, jam	34	0.549	0.549
Meat	34	8.678	8.678
Poultry	34	13.256	13.256
Fish	25	3.975	3.975
Soft drinks	166	2.157	2.157
Miscellaneous	36	9.468	9.468
Bread*	119	18.669	■
Cheese*	16	15.117	■
Potatoes*	157	80.698	■
Fruit*	147	48.818	■
Meat products*	66	15.816	■
Alcohol/wine	129	9.131	■
Oils, fats	uq	0	0
Spinach**	uq	0	0
Mayonnaise**	uq	0	0
Raisin**	uq	0	0
Tuna (in oil)**	uq	0	0
Garlic**	10	0.07	0.07
Dill**	10	0.07	0.07
Kiwi**	30	0.21	0.21
Pineapple**	30	0.21	0.21
Total	1466	309.54	125.07

Notes: # Таблица представлена с рекомендациями авторов, * - пища, которая нами удалена из диеты, ** - пища, в которой отсутствуют полиамины, uq -unlimited quantity

surface of target cells, translation and replication of daughter viruses [Mounce B et al., 2016 a,b; Avagyan S et al., 2020; Firpo M, Mounce B, 2020; Firpo M et al., 2020; Zilfyan A et al., 2020]. Moreover, aliphatic polyamines are involved in the nucleocapsid packaging of some human pathogenic coronaviruses.

It was the “vital” need of polyamines for SARS-CoV-2, which largely ensure the processes of long-term persistence of the coronavirus in the body, that served as the basis for the recommendations to include agents blocking the exchange of polyamines in the infected organism in the general registry of symptomatic therapy for COVID-19 [Mounce B et al., 2017; Zilfyan A et al., 2021; Avagyan S et al., 2021]. These agents include α -difluoromethylornithine (DFMO), which inhibits the initial steps of aliphatic polyamine synthesis by blockade of ornithine decarboxylase [Meykens F, Gerner E, 1999]. Unfortunately, such an approach, based on the use of DFMO as a complex therapy for COVID, has not been properly evaluated yet. It should also be noted that at present we do not have even minimal information about the features of aliphatic polyamine metabolism in a SARS-CoV-2 infected organism. In our opinion, this situation requires the implementation of scientific and organizational measures in specialized clinical laboratories, where the levels of aliphatic polyamines – putrescine, spermidine and spermine should be determined in the bioassays taken from COVID-19 patients.

Since there are no significant changes in this issue, a polyamine-deficient diet should be considered today as possible effective means of symptomatic and, especially, pathogenetic therapy for COVID-19.

In fact, we propose an alternative approach based on the significant elimination of food products containing high levels of aliphatic polyamines entering into the infected organism. Due to this approach, it will be possible to minimize the level of polyamines in target cells and, thereby, achieve a noticeable inhibition of polyamine-dependent processes responsible for the persistence and enhancement of the biological activity of SARS-CoV-2 in an infected organism.

It should be especially noted that the entire list of foods that we will present as a polyamine-defi-

cient diet, along with numerous products of animal and vegetable origin, is used in everyday life, without any restrictions for a healthy contingent of people living in many regions of the globe, as well as in a wide range of somatic diseases, including those of infectious origin. At present, the diet of COVID-19 patients also includes food products with a high content of aliphatic polyamines – putrescine, spermidine and spermine.

As we mentioned above, our recommendations are based on one important scientific and methodological principle in the process of studying the COVID-19 pathogenesis, in which SARS-CoV-2 urgently needs polyamines for its persistence. That's why, on the one hand, we propose, if possible, to exclude a wide range of food products that are rich in polyamines. On the other hand, we adhere to the maximum intake of those foods that are characterized by the lowest content of polyamines or their complete absence.

In this article we provide a list of products of animal and vegetable origin as a “polyamine-deficient” diet, which should be followed by both COVID-19 patients and a wide contingent of apparently healthy individuals and convalescents (table 5). Unfortunately, to date, there is no such experience associated with the use of a polyamine-deficient diet in patients infected with SARS-CoV-2 in any country.

Apparently, this is our first attempt to introduce the principle of a polyamine-deficient diet for COVID-19 patients, which may undergo corrections with the introduction of new recommendations.

It should be noted that our own recommendations on the need for a polyamine-deficient diet for COVID-19 were summarized in our previous publication [Avagyan S et al., 2021; Cipolla B et al., 2003; Muñoz-Esparza N, 2019] with several tables (due to the synthesis of numerous highly informative data) that presented a wide range of animal and vegetable products, characterized by both high and low content of aliphatic polyamines. Due to this circumstance, there was a need for new recommendations on the use of more specific, most commonly used products, with a low content of aliphatic polyamines, regardless of the region of residence of a healthy and SARS-CoV-2 infected con-

tingent of individuals.

Polyamine-deficient products of animal and vegetable origin recommended by us for COVID-19 patients, both during the period of SARS-CoV-2 infection and the height of the disease, and during clinical recovery (at least for several years after infection) are presented in table 5.

Food products with a high content of putrescine in them should be excluded from the general diet of COVID-19 patients. As an example, it's enough to cite very informative data on the content of aliphatic polyamines in food products, which are presented in a summary table [Ali A et al., 2011]. The same data of the above-mentioned authors are given in our book and review article [Avagyan S, Zilfyan A, 2019; Avagyan S et al., 2020].

To ensure vitamin C intake, it is recommended to eat foods with a high content of vitamin C (even several times higher than its content) and with a low content of polyamines instead of some fruits in which the content of polyamines is very high (oranges, grapefruits, tangerines). Rose hips, green peppers and some other products can be very effective in replacing citrus for COVID-19 patients, as their vitamin C content is several times higher than that of citrus fruits, and the level of polyamines is much lower.

Drinking red wines is not excluded, as well as chocolate in relatively minimal quantities.

Reviewing and analyzing the obtained results, we found necessary to exclude those food products (from the list of products taken during COVID-19) that contain the highest content of putrescine: sauerkraut, green peppers, fried potatoes and green onions, ketchup. Among the meat products and their derivatives is goose and chicken liver pate.

The distribution of aliphatic polyamines in various food products of animal and vegetable origin often varies widely. Therefore, physicians and nutritionists should follow the principle of selective approach when prescribing a polyamine-deficient diet to COVID-19 patients and convalescents. When choosing a diet, clinicians should be based on chromatographic study results (high performance liquid chromatography) aimed at determining the level of aliphatic polyamines in the blood of COVID-19 patients and convalescents: putrescine, spermidine and spermine.

In this selective approach, we recommend the

use of freshly made pomegranate juice, or the pomegranate itself with seeds, and green tea, since the expected effect depends on the properties of both products. Firstly, pomegranate is characterized by the absence of polyamines in it. Secondly, and more significantly, both products have a unique ability to inhibit the synthesis of aliphatic polyamines in the macroorganism, by blocking the ornithine decarboxylase activity, thereby preventing the synthesis of putrescine from ornithine.

For prophylactic purposes we also recommend to use all food products offered during the pandemic as a polyamine-deficient diet to a wide contingent of practically healthy individuals, convalescents, medical staff of specialized clinics, as well as family members of SARS-CoV-2 infected patients.

All the fruits listed in table 6, which have high levels of aliphatic polyamines, must be excluded from the list of nutritional products of not only COVID-19 patients, but also practically healthy individuals, medical personnel of specialized infectious diseases clinics, as well as family members of SARS-CoV-2 infected patients.

While preparing polyamine-free and polyamine-deficient diets, one should, in our opinion, adhere to the following tactics.

First, it is necessary to determine the levels of polyamines in plasma, erythrocytes and urine of patients with modern methods of diagnostic tests. It is advisable to determine not only the levels of putrescine, spermidine and spermine, but also to

Table 6

Aliphatic polyamine levels in fruits that have to be excluded from the list of nutritional products of COVID-19 patients

Fruits	Polyamine ($\mu\text{mol/g}$)		
	Put	Spd	Spm
Orange	620-1360	27-93	-
Philippine mango	903	199	16
Tangerine	860	80	-
Ruby grapefruit	580	20	-
Grapefruit	292	19	3
Banana	180-466	60	-
Grape	105	87	-
Cherry	53	19	-

NOTES: Put - putrescine, Spd - spermidine, Spm Spermine

include cadaverine and agmatine in this list, given that high performance liquid chromatographic (HPLC) analysis allows them to be determined simultaneously in the same sample [Hockl P et al., 2000; Taibi G et al., 2000; Aflaki F et al., 2014].

Secondly, a nutritionist must necessarily participate in preparing a diet, who must be familiar with the results of laboratory biochemical studies for the determination of polyamines.

When formulating a polyamine-deficient diet, the nutritionist should pay special attention to the fact that the levels of polyamine combinations in different products manifest themselves in different ways. For example, if the levels of putrescine in patient's blood are higher than spermine and spermidine based on a diagnostic test, the nutritionist should exclude specific food products containing high levels of putrescine from the general diet. A similar approach should be followed by a nutritionist when taking into account the indicators of spermidine and spermine in patient bioassays.

CONCLUSION

It is necessary to study the changes in polyamine levels and establish diagnostic indicators characteristic of each disease in patients with "polyamine-dependent" diseases, particularly with viral infections.

We propose the above list of food products for the first time as a polyamine-deficient diet for COVID-19 patients, a wide contingent of practically healthy individuals, medical personnel of specialized infectious disease clinics, as well as

family members of SARS-CoV-2 infected patients.

In our opinion, the recommended polyamine-deficient diet is based on scientifically substantiated study results of a number of advanced scientists and the results of our own observations.

The polyamine-deficient diet is mainly based on COVID-19 pathogenesis, which, in particular, is expressed by the "uptake" of polyamines from target cells by SARS-CoV-2. As a result, long-term persistence of the coronavirus in the macroorganism is ensured by activating its adhesive properties, intracellular translation and replication of daughter viruses.

That is why the proposed polyamine-deficient diet seems to be most likely pathogenetically justified, since it will, to a certain extent, significantly inhibit the SARS-CoV-2 persistence in the infected organism.

This is our first attempt to include in the diet such food products of animal and vegetable origin that contain an extremely low content of aliphatic polyamines – putrescine, spermidine and spermine.

The "scheme" of the polyamine-deficient diet, proposed by us, is, of course, not exhaustive and, moreover, a panacea. The choice of all the products included in the list of the polyamine diet at the same time cannot serve as a prerequisite. The attending physicians should adjust the use of food products themselves after prior consultation with "competent" nutritionists, however, always subject to the conditions for choosing exactly those products that we recommend as a polyamine-deficient diet for COVID-19 patients.

REFERENCES

1. Aflaki F, Ghoulipour V, Saemian N, Salahinejad M (2014). A simple method for benzoyl chloride derivatization of biogenic amines for high performance liquid chromatography. *Analytical Methods*. 6(5): 1482
2. Atiya Ali M, Poortvliet E, Stromberg R, Yngve A (2011). Polyamines in foods: development of a food database. *Food & Nutrition Research*. 55
3. Atiya Ali M, Strandvik B, Palme-Kilander C, Yngve A. (2013). Lower polyamine levels in breast milk of obese mothers compared to mothers with normal body weight. *Journal of Human Nutrition and Dietetics*. 26(1): 164-170
4. Atiya Ali M, Yngve A (2009). Polyamines: Dietary intake, database progress and food contribution to the total daily intake. *Annals of Nutrition & Metabolism*. 55: 203-204
5. Avagyan SA, Muradyan AA, Zilfyan AV (2021). Certain Approaches While Choosing the Strategy of Covid-19 Pathogenetic Therapy and Immunoprophylaxis. *The New Armenian Medical Journal*. 15(2): 4-18
6. Avagyan SA, Zilfyan AV, Muradyan AA, Ghazaryan VJ, Ghazaryan HV (2020). New perspectives for the treatment and prevention of COVID-19 infection. The role of polyamine-

- dependent mechanisms in the life cycle of RNA and DNA viruses in mammals. The New Armenian Medical Journal. 14(4): 108-122
7. Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC., et al (2021). Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States. MMWR Morb Mortal Wkly Rep 70: 1294-1299
 8. Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC., et al (2021). Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization – Five Veterans Affairs Medical Centers, United States. MMWR Morb Mortal Wkly Rep. 70: 1294-1299
 9. Binh PN, Soda K, Kawakami M (2011). Mediterranean diet and polyamine intake: possible contribution of increased polyamine intake to inhibition of age-associated disease. Nutr Diet Suppl. 3: 1-7
 10. Bitsadze BO, Grigoreva K, Khizroeva JKh, Pervunina TM, Tsibizova VI., et al (2020). Novel coronavirus infection and Kawasaki disease. The Journal of Maternal-Fetal & Neonatal Medicine. J Matern Fetal Neonatal Med. 35(16): 3044-3048
 11. Buyukuslu N, Hizli H, Esin K, Garipagaoglu M (2014). A Cross-Sectional Study: Nutritional Polyamines in Frequently Consumed Foods of the Turkish Population. Foods. 3(4): 541-557
 12. Chaturvedi R, de Sablet T, Coburn LA, Gobert AP, Wilson KT (2012). Arginine and polyamines in Helicobacter pylori-induced immune dysregulation and gastric carcinogenesis. Amino Acids. 42(2-3), 627-640
 13. Chen Y, Xu Z, Wang P, LiX M, Shuai ZW., et al (2022). New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 165: 386-401
 14. Cipolla B, Guillé F, Moulinoux JP (2003). Polyamine-reduced diet in metastatic hormone-refractory prostate cancer (HRPC) patients. Biochemical Society Transactions. 31(2): 384-387
 15. Cipolla BG, Havouis R, Moulinoux JP (2007). Polyamine contents in current foods: a basis for polyamine reduced diet and a study of its long term observance and tolerance in prostate carcinoma patients. Amino Acids. 33: 203-212
 16. Cizmeci PK Fischinger S, Collier AR, Suscovich T, Linde C., et al (2022). mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 14(645): eabm2311
 17. Eliassen KA, Reistad R, Risoen U, Ronning HF (2002). Dietary polyamines. Food Chem. 78: 273-280
 18. Gómez GC, Kumar H, García MI, du Toit E, Suomela JP., et al (2017). Breast milk polyamines and microbiota interactions: impact of mode of delivery and geographical location. Ann Nutr Metab. 70: 184-190
 19. Gondalia SV, Mahon PJ, Palombo EA, Knowles SR, Austin DW (2013). Evaluation of Biogenic Amines in the Faeces of Children with and without Autism by LC-MS/MS. International Journal of Biotechnology and Biochemistry. 9(2): 245-255
 20. Gugliucci A (2004). Polyamines as clinical laboratory tools. Clin Chimica Acta. 344: 23-25
 21. Hockl PF, Thyssen SM, Libertun C (2000). An improved HPLC method for identification and quantitation of polyamines and related compounds as benzoylated derivatives. Journal of Liquid Chromatography & Related Technologies. 23(5): 693-703
 22. Howard-Jones AR, Burgner DP, Crawford NW, Goeman E, Gray PE., et al (2022). COVID-19 in children. II: Pathogenesis, disease spectrum and management, Journal of Pediatrics and Child Health. 58: 46-53
 23. Kalač P (2014). Health effects and occurrence of dietary polyamines: A review for the period 2005-mid 2013. Food Chemistry. 161: 27-39
 24. Kannan M, Sathiyarajeswaran P, Sasikumar D, Geetha A, Mohanapriya M., et al (2022). Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients. Journal of Ayurveda and Integrative Medicine. 13(3): 100589
 25. Kobayashi T, Nishiura H (2022). Prioritizing COVID-19 vaccination. Part 1: Final size comparison between a single dose and double dose. Mathematical Biosciences and Engineering. 19(7): 7374-7387
 26. Larqué E, Sabater Molina M, Zamora S (2007).

- Biological significance of dietary polyamines. *Nutrition*. 23: 87-95
27. Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX., et al (2022). Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. *BMJ*. 376: e068632
 28. Lewandowski NM, Ju S, Verbitsky M, Ross B, Geddie, ML., et al (2010). Polyamine pathway contributes to the pathogenesis of Parkinson disease. *Proceedings of the National Academy of Sciences*. 107(39): 16970-16975
 29. Loser C, Eisel A, Harms D, Folsch UR (1999). Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. *Gut*. 44(1): 12-16
 30. Makhoba XH, Makumire S (2022). The capture of host cell's resources: The role of heat shock proteins and polyamines in SARS-CoV-2 (COVID-19) pathway to viral infection. *Bio-molecular Concepts*. 13: 220-229
 31. Meyskens FL, Gerner EW (1999). Development of difluoromethylornithine (DFMO) as a hemoprevention agent. *Clin Cancer Res*. 5(5): 945-951
 32. Moinard C, Cynober L, de Bandt JP (2005). Polyamines: metabolism and implications in human diseases. *Clin Nutr*. 24: 184-197
 33. Moulinoux Ph, Quemener V, Cipolla B, Guillé F, Havouis R., et al (1991). The Growth of MAT-LyLu Rat Prostatic Adenocarcinoma can be Prevented in Vivo by Polyamine Deprivation. *J Urol*. 146(5): 1408-1412
 34. Mounce BC, Cesaro T, Moratorio G, Hooikaas PJ, Yakovleva A., et al (2016a). Inhibition of polyamine biosynthesis is a broad-spectrum strategy against RNA viruses. *J Virol*. 90(21): 9683-9692
 35. Mounce BC, Olsen ME, Vignuzzi M, Connor JH (2017). Polyamines and Their Role in Virus Infection. *Microbiology and Molecular Biology Reviews*. 81(4): e00029-17.
 36. Mounce BC, Poirier EZ, Passoni G, Simon-Loriere E, Cesaro T., et al (2016b). Interferon-Induced Spermidine-Spermine Acetyltransferase and Polyamine Depletion Restrict Zika and Chikungunya Viruses. *Cell Host Microbe*. 20(2): 167-177
 37. Muñoz-Esparza NC, Latorre-Moratalla ML, ComasBasté O, Toro-Funes N, Veciana-Nogués MT, Vidal-Carou MC (2019). Polyamines in Food Front *Nutr*. 6: 108
 38. Paik MJ, Ahn YH, Lee PH, Kang H, Park CP., et al (2010). Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy. 411(19-20), 1532-1535
 39. Ralph A, Englyst K, Bardocz S (1999). Polyamine content of the human diet. In *Polyamines in Health and Nutrition*; Bardocz, S., White, A., Eds.; Kluwer Academic Publishers: London, UK. 123-137
 40. Rolfo A, Cosma S, Nuzzo AM, Salio C, Moretti L., et al (2022). Increased Placental Anti-Oxidant Response in Asymptomatic and Symptomatic COVID-19 Third-Trimester Pregnancies *Biomedicines*. 10(3): 634
 41. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J., et al (2022). Covid-19 Vaccine Effectiveness in New York State, January 13, 2022. *N Engl J Med*. 386: 116-127
 42. Ruiz CD, Pérez LIF, Zamora S (2012). Implicaciones de las poliaminas en la salud infantil. *Arch Argent Pediatr*. 110: 244-250
 43. Schipper RG, Penning LC, Verhofstad AA (2000). Review: involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? *Semin Cancer Biol*. 10: 55-68
 44. Shrestha RD, Fujimoto S, Okui K (1992). A novel anticancer treatment for xenoplated human gastric cancer, using polyamine antimetabolites in a low polyamine diet. *Surg Today*. 22(2): 137-142
 45. Smythies J (2012). The Role of Abnormalities Related to the One Carbon Cycle in Depression and Schizophrenia. *Neuroscience & Medicine*. 3: 101-106
 46. Soda K, Kano Y, Sakuragi M, Takao M, Lefor A, Konishi F (2009). Long-Term Oral Polyamine Intake Increases Blood Polyamine Concentrations. *Journal of Nutritional Science and Vitaminology*. 55: 361-366
 47. Tabor C, Tabor H (1984). Polyamines. *Annu Rev Biochem*. 53: 749-790
 48. Taibi G, Schiavo MR, Gueli MC, Rindina PC, Muratore R, Nicotra CM (2000). Rapid and simultaneous high-performance liquid chromatog-

- raphy assay of polyamines and monoacetyl polyamines in biological specimens. 745(2): 431-437
49. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ., et al (2021). Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥ 65 Years – United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 70: 674-679
50. Wang Ni, Yang MB, Yang PY, Chen RB, Huang F., et al (2022). A Case Series of Olfactory Dysfunction in Imported COVID-19 Patients: A 12-Month Follow-Up Study, Biomedical and Environmental Sciences. 35(5): 402-411
51. Xie Y, Xu E, Bowe B, Al-Aly Z (2022). Long-term cardiovascular outcomes of COVID-19. Nat Med. 28: 583-590
52. Xu X, Zhang W, Guo M, Xiao C, Fu Z., et al (2022). Integrated analysis of gut microbiome and host immune responses in COVID-19. Front Med. 16(2): 263-275
53. Zilfyan AV, Avagyan SA, Muradyan AA, Ghazaryan VJ, Ghazaryan HV (2020). Possible role of aliphatic polyamines in the inhibition process of daughter viruses' replication in COVID-19 infection. Expediency of adding α -difluoromethylornithine to the registry of drugs for COVID-19 infection. The New Armenian Medical Journal. 14(4): 4-15
54. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner WW, Meyskens Jr FL (2007). Development of a Polyamine Database for Assessing Dietary Intake. 107(6): 1024-1027
55. Hotez PJ, Bottazzi ME (2022). Whole Inactivated Virus and Protein-Based COVID-19 Vaccines, Annual Review of Medicine. 73: 55-64
56. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W (2022). Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 114: 252-260
57. Abu-Raddad LJ, Chemaitelly H, Butt AA (2021). National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 385: 187-189



CONTENTS

4. **SARGSYAN D., CABRERA J., KOSTIS J.B., FAHIM M., BEAVERS T., ZINONOS S., HSU V., MEKINIAN A., KOSTIS W.J.**
A STATEWIDE STUDY OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
14. **AVAGYAN S.A., ZILFYAN A.V., MURADYAN A.A.**
NEW APPROACHES RELATED TO THE USE OF POLYAMINE-FREE AND POLYAMINE-DEFICIENT DIETS IN THE LIST OF NUTRITIONAL PRODUCTS FOR COVID-19 PATIENTS
25. **WARDHANA M.P., TUMANGGER D., JUWONO H.J., ERNAWATI E., RIFDAH S.N., WAFA I.A., KUNTAMAN K., DACHLAN E.G.**
THE EXPLORATION OF INFLAMMATORY AND COAGULATION BIOMARKERS BETWEEN PREGNANT WOMEN WITH AND WITHOUT COVID-19
33. **HOVHANNISYAN A.H., ASOYAN V.A., GYULAZYAN N.M., MADATYAN A.A., POGHOSYAN A.H., MOHAMMADI M., BARSEGHYAN E.S.**
COVID-19 INFECTION AND BUERGER'S SYNDROME: A CASE REPORT
38. **MAKSIMOVA E.V., KLIARITSKAIA I.L., STILIDI E.I., GRIGORENKO E.I., MOSHKO YU.A.**
INFLUENCE OF CHANGES IN THE INTESTINAL MICROBIOME ON THE COURSE AND PROGRESSION OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE
45. **ARTONO A., PURNAMI N., HANDOKO E., MOON I.S., JANITRA S.N.**
CORRELATION BETWEEN THE PERFORATION SIZE AND PATENCY OF EUSTACHIAN TUBE AND GRAFT UPTAKE IN INTACT CANAL WALL TYMPANOPLASTY SURGERY: A STUDY OF 32 BENIGN-TYPE CHRONIC SUPPURATIVE OTITIS MEDIA PATIENTS
51. **PUTRI F.R., KURNIAWATI E.M., TIRTHANINGSIH N.W.**
RISK FACTORS FOR POSTPARTUM HEMORRHAGE CAUSED BY UTERINE ATONY
60. **MOTAMED H., MEHRABI M.**
CAN SERUM AMYLASE LEVEL EVALUATION FACILITATE EARLY DIAGNOSIS OF ACUTE APPENDICITIS, AS AN ADJUNCTIVE BIOMARKER?
66. **BELLANNY D.D., PERDANA R.F.,**
CASE REPORT OF FATAL DEEP NECK ABSCESS: A COMPLICATION OF AERODIGESTIVE FOREIGN BODIES
76. **EBRAHIMI S.M., MOTAMED H., KALANTAR H., KALANTARI A., RAHIM F.**
HOSPITAL ADMISSIONS DUE TO SHORT-TERM EXPOSURE TO AIR POLLUTION: A SCOPING REVIEW
91. **KARIMPOUR F.F., AFROUGHI S.**
PREVALENCE OF WEIGHT STATUS AND ASSOCIATED FACTORS OF UNDERWEIGHT AMONG THE MEDICAL STUDENTS IN IRAN
100. **MARKOSYAN R. L., BABAYAN H.N.**
GRAVES DISEASES WITH SEVERE PROGRESSIVE OPHTHALMOPATHY AFTER THYROIDECTOMY. CASE REPORT.
104. **KHANCHI M., MATKERIMOV A.ZH., TERGEUSSIZOV A.S., DEMEUOV T.N., ZHAKUBAYEV M.A., KHANCHI M.M., BAUBEKOV A.A., TAJIBAYEV T.K., YERKINBAYEV N.N., SADUAKAS A.E., MAKHAMOV R.O.**
SURGICAL TREATMENT OF VISCERAL AND RENAL ABDOMINAL ARTERY ANEURYSMS OF VARIOUS ETIOLOGY
113. **ALARSAN S.F.**
PALLIATIVE CARE: A CONCEPT ANALYSIS
118. **ASHWANI K., RAGHAVENDRA R., SUJATHA B.**
EFFECTIVENESS OF PLATELET INDICES IN PREDICTING TYPE 2 DIABETES MELLITUS MICROVASCULAR COMPLICATIONS



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.



Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37410) 580840 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

*Our journal is registered in the databases of Scopus,
EBSCO and Thomson Reuters (in the registration process)*



SCOPUS



EBSCO



THOMSON
REUTERS

Copy editor: Tatevik R. Movsisyan

Printed in "VARM" LLC
Director: Ruzanna Arakelyan
Armenia, 0018, Yerevan,
Tigran Mec 48, 43
Phone: (+374 91) 19 29 00,
E-mail: armana6@mail.ru

Editor-in-Chief

Arto V. Zilfyan (Yerevan, Armenia)

Deputy Editors

Hovhannes M. Manvelyan (Yerevan, Armenia)

Hamayak S. Sisakyan (Yerevan, Armenia)

Executive Secretary

Stepan A. Avagyan (Yerevan, Armenia)

Editorial Board

Armen A. Muradyan (Yerevan, Armenia)

Drastamat N. Khudaverdyan (Yerevan, Armenia)

Levon M. Mkrtchyan (Yerevan, Armenia)

Foregin Members of the Editorial Board

Carsten N. GUTT (Memmingen, Germany)

Muhammad MIFTAHUSSURUR (Indonesia)

Alexander WOODMAN (Dharhan, Saudi Arabia)

Hesam Adin Atashi (Tehran, Iran)

Coordinating Editor (for this number)

Inkar Sagatov (Almaty, Kazakhstan)

Editorial Advisory Council

Ara S. Babloyan (Yerevan, Armenia)

Aram Chobanian (Boston, USA)

Luciana Dini (Lecce, Italy)

Azat A. Engibaryan (Yerevan, Armenia)

Ruben V. Fanarjyan (Yerevan, Armenia)

Gerasimos Filippatos (Athens, Greece)

Gabriele Fragasso (Milan, Italy)

Samvel G. Galstyan (Yerevan, Armenia)

Arthur A. Grigorian (Macon, Georgia, USA)

Armen Dz. Hambardzumyan (Yerevan, Armenia)

Seyran P. Kocharyan (Yerevan, Armenia)

Aleksandr S. Malayan (Yerevan, Armenia)

Mikhail Z. Narimanyan (Yerevan, Armenia)

Levon N. Nazarian (Philadelphia, USA)

Yumei Niu (Harbin, China)

Linda F. Noble-Haeusslein (San Francisco, USA)

Arthur K. Shukuryan (Yerevan, Armenia)

Suren A. Stepanyan (Yerevan, Armenia)

Gevorg N. Tamamyanyan (Yerevan, Armenia)

Hakob V. Topchyan (Yerevan, Armenia)

Alexander Tsiskaridze (Tbilisi, Georgia)

Konstantin B. Yenkovyan (Yerevan, Armenia)

Peijun Wang (Harbin, China)